Research Comparison
Cagrilintide (AM833) vs Retatrutide (LY3437943)
A side-by-side research comparison of Cagrilintide (AM833) and Retatrutide (LY3437943) drawn from Cobalt Peptides' peptide database records.
Cagrilintide (AM833)
Cagrilintide (AM833) is a long-acting, lipidated amylin analogue with activity at both amylin and calcitonin receptors. Its acylation gives an extended half-life suited to once-weekly administration in study protocols, and it has been investigated both alone and alongside GLP-1 receptor agonists in published metabolic research. Cagrilintide is not an approved medicine and remains investigational. Supplied strictly as a research compound for laboratory use.
Retatrutide (LY3437943)
Retatrutide (LY3437943) is an investigational triple hormone receptor agonist with activity at the GLP-1, GIP and glucagon receptors. Its design combines incretin-axis signalling through GLP-1 and GIP with glucagon receptor activity, a combination studied for its effects on energy balance in published metabolic research. Retatrutide is not an approved medicine in the United Kingdom or elsewhere and remains in clinical development by its originator. Supplied strictly as a research compound for laboratory use.